Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

The Challenge of Primary Central Nervous System Lymphoma.

Carnevale J, Rubenstein JL.

Hematol Oncol Clin North Am. 2016 Dec;30(6):1293-1316. doi: 10.1016/j.hoc.2016.07.013. Review.

PMID:
27888882
2.

Current approaches and advance in mantle cell lymphoma treatment.

Liu Y, Zhang X, Zhong JF.

Stem Cell Investig. 2015 Sep 29;2:18. doi: 10.3978/j.issn.2306-9759.2015.09.02. Review.

3.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-51. doi: 10.1016/j.bbmt.2016.04.019. Review.

4.

Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.

Salvino MA, Ruiz J.

Rev Bras Hematol Hemoter. 2016 Jan-Feb;38(1):28-36. doi: 10.1016/j.bjhh.2015.07.011.

5.

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network..

Haematologica. 2016 Feb;101(2):104-14. doi: 10.3324/haematol.2014.119115. Review.

6.

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes.

Vallumsetla N, Paludo J, Kapoor P.

Ther Clin Risk Manag. 2015 Nov 6;11:1663-74. doi: 10.2147/TCRM.S72943. Review.

7.

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.

Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK.

Br J Haematol. 2015 Dec;171(5):788-97. doi: 10.1111/bjh.13773.

8.

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN 3rd, Bensinger WI, Shadman M, Maloney DG, Press OW, Gopal AK.

Biol Blood Marrow Transplant. 2016 Feb;22(2):380-5. doi: 10.1016/j.bbmt.2015.08.035.

PMID:
26348890
9.

New approaches in primary central nervous system lymphoma.

Fraser E, Gruenberg K, Rubenstein JL.

Chin Clin Oncol. 2015 Mar;4(1):11. doi: 10.3978/j.issn.2304-3865.2015.02.01. Review.

10.

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010.

Issa DE, van de Schans SA, Chamuleau ME, Karim-Kos HE, Wondergem M, Huijgens PC, Coebergh JW, Zweegman S, Visser O.

Haematologica. 2015 Apr;100(4):525-33. doi: 10.3324/haematol.2014.107300.

11.
12.

Non-Hodgkin's lymphomas, version 4.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H; National comprehensive cancer network..

J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303.

13.

Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.

Desai M, Newberry K, Ou Z, Wang M, Zhang L.

Ther Adv Hematol. 2014 Jun;5(3):91-101. doi: 10.1177/2040620714532124. Review.

14.

Progress in central nervous system lymphomas.

Wang CC, Carnevale J, Rubenstein JL.

Br J Haematol. 2014 Aug;166(3):311-25. doi: 10.1111/bjh.12938. Review.

15.

Autologous stem cell transplantation for mantle cell lymphoma - single centre experience.

Szcześniak M, Armatys A, Kurzawa R, Kandzia T, Kozioł D, Frankiewicz A, Kopińska A, Krawczyk-Kuliś M, Kyrcz-Krzemień S, Helbig G.

Contemp Oncol (Pozn). 2013;17(5):456-9. doi: 10.5114/wo.2013.37223.

16.

Reply to M.C. Chamberlain.

Rubenstein JL, Cheson BD, Jung SH, Kaplan LD.

J Clin Oncol. 2014 Mar 10;32(8):858-9. doi: 10.1200/JCO.2013.53.8942. No abstract available.

17.

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

Chang JE, Li H, Smith MR, Gascoyne RD, Paietta EM, Yang DT, Advani RH, Horning SJ, Kahl BS.

Blood. 2014 Mar 13;123(11):1665-73. doi: 10.1182/blood-2013-08-523845.

18.

How I treat CNS lymphomas.

Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P.

Blood. 2013 Oct 3;122(14):2318-30. doi: 10.1182/blood-2013-06-453084.

19.

Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.

Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1403-6. doi: 10.1016/j.bbmt.2013.07.005.

20.

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, Caballero D.

Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377.

Items per page

Supplemental Content

Support Center